{"id":"l-arginine-l-arginine-veyron","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbance"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"L-arginine acts as a precursor for nitric oxide (NO) synthesis via the enzyme nitric oxide synthase. Increased NO production leads to vasodilation, improved endothelial function, and enhanced blood flow. This mechanism underlies its use in cardiovascular and vascular disorders where endothelial dysfunction is a contributing factor.","oneSentence":"L-arginine is a semi-essential amino acid that serves as a substrate for nitric oxide synthase, increasing nitric oxide production to improve vascular function and blood flow.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:51:16.764Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Vascular dysfunction and endothelial dysfunction"},{"name":"Cardiovascular disease management"}]},"trialDetails":[{"nctId":"NCT02117206","phase":"PHASE4","title":"Protective Effects of L-arginine During Reperfusion by Femoropopliteal Bypass for Lower Limb Ischemic Syndrome in Humans","status":"COMPLETED","sponsor":"University Hospital, Strasbourg, France","startDate":"2005-11","conditions":"Skeletal Muscle Ischemia, Severe Lower Limb Ischemia, Mitochondrial Dysfunction","enrollment":60},{"nctId":"NCT00549575","phase":"PHASE3","title":"L-Arginine Treatment for Severe Vascular Fetal Intrauterine Growth Restriction: a Randomized Double Bind Controlled Trial (L Arginine in IUGR)","status":"TERMINATED","sponsor":"Nantes University Hospital","startDate":"2000-07","conditions":"Intra Uterine Growth Retardation","enrollment":44}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"L-arginine (L-arginine Veyron)","genericName":"L-arginine (L-arginine Veyron)","companyName":"University Hospital, Strasbourg, France","companyId":"university-hospital-strasbourg-france","modality":"Small molecule","firstApprovalDate":"","aiSummary":"L-arginine is a semi-essential amino acid that serves as a substrate for nitric oxide synthase, increasing nitric oxide production to improve vascular function and blood flow. Used for Vascular dysfunction and endothelial dysfunction, Cardiovascular disease management.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}